Table 2. Quantitative evaluation of 22 genes containing multiple TSSs (multiple variable first exons) by real-time PCR.

		Change in expression level compared to the 0-day sample				Expression			
Gene symbol	cDNA name	1-day	2- days	7- days	14- days	35- days	pattern	Gene description	References
AGPS	FLJ51873 NM 003659.1	± ±	± ±	Up ±	± ±	Up ±	Differ	alkylglycerone phosphate synthase	[128]
AKT1	FLJ53606 NM 005163.2	± ±	± ±	Up	Up (169)	Up (416)	Differ	v-akt murine thymoma viral oncogene homolog 1	[10, 119, 120
ARHGEF3	FLJ55856	±	±	± ±	± Dn	± ±	Differ	Rho guanine nucleotide exchange factor	[133, 134]
	FLJ55591	±	±	±	±	±	Differ	(GEF) 3	[133, 134]
	NM 019555.1	±	±	±	±	Up			
CRISPLD1	FLJ57290	±	±	±	±	Up	Differ	cysteine-rich secretory protein LCCL domain	[132]
	NM_031461.3	±	±	±	±	±		containing 1	. ,
YSF	FLJ55344	±	±	±	±	±	Differ	dysferlin, limb girdle muscular dystrophy 2B	[123, 124]
	NM_003494.2	±	±	±	Dn	Dn (295)		(autosomal recessive)	
FAM65B	FLJ56137	±	±	Up	±	±	Differ	family with sequence similarity 65, member B	[10, 131]
	AB002384.1	±	±	±	±	Up			
	NM_015864.2	± .	±	±	Dn	±	D:00	FYVE, RhoGEF and PH domain containing 4	F10 125 126
FGD4	FLJ56188	±	±	Up	±	Up	Differ	FYVE, Knoger and PH domain containing 4	[10, 135, 136
	FLJ55905 NM 139241.1	± ±	± ±	± ±	Dn ±	±			
HDAC9	FLJ55607	±	±		±	±	Differ	histone deacetylase 9	[137]
ПВАС	FLJ54577	±	±	±	±	±	Dinei		[12/]
	NM 178423.1	±	±	±	Dn	±			
MAGI2	FLJ99053	±	±	±	±	Up	Differ		[130]
	FLJ50810	±	±	±	±	±		and PDZ domain containing 2	
	NM_012301.3	±	±	Up	±	Up			
MAP7	FLJ56145	±	±	Up (1,352)	Up (256)	Up (223)	Differ	microtubule-associated protein 7	[127]
	FLJ50558	±	±	Up	±	Up			
	FLJ50557	±	±	±	±	Up			
	FLJ78961	±	±	Up	±	Up			
(CE2	NM_003980.3	± .	±	± .	±	±	D:00	MCF 2 Il line desired town formalise	F1203
1CF2	FLJ51685	±	± D	±	±	±	Differ	MCF.2 cell line derived transforming sequence	[138]
NCAM2	NM_005369.2 FLJ54289	± ±	Dn ±	± ±	± ±	± Up	Differ	neural cell adhesion molecule 2	[139]
	FLJ53114	±	±	±	±	Up	Dillei	neural cen adnesion molecule 2	[139]
	NM 004540.2	±	±	±	±	±			
NEDD4L	FLJ53199		±	Up	±	Dn	Differ	neural precursor cell expressed,	[140]
	FLJ61249	±	±	±	±	±		developmentally down-regulated 4-like	,
	NM_015277.2	±	±	±	土	±			
OXR1	FLJ42450	±	±	Up	±	±	Differ	oxidation resistance 1	[10, 141]
	NM_181354.3	±	±	±	±	±			
	FLJ55036	±	±	±	±	±			
PEX5L	FLJ50526	±	±	±	±	±	Differ	peroxisomal biogenesis factor 5-like	[142]
	FLJ53911	±	Dn	±	Dn	±			
	FLJ50489	±	Dn Dn	± Dn	Dn Dn	±			
PPP2R2C	NM_016559.1 FLJ58008	± ±	Dn ±	Dn ±	Dn Dn	± ±	Differ	protein phosphatase 2, regulatory subunit B,	[143]
1112K2C	NM 020416.2	±	±	± ±	Dn ±	± ±	Dillel	gamma	[143]
RAPGEF4	FLJ50956		±	±	±	±	Differ	Rap guanine nucleotide exchange factor	[121, 122]
	FLJ58368	±	Up	Up (892)	Up (148)	Up (1,024)		(GEF) 4	,,
	FLJ51189	Up	Up	Up (338)	Up	Up			
	NM_007023.1	±	±	±	±	±			
SEMA5B	FLJ55460	±	±	±	±	±	Differ	sema domain, seven thrombospondin repeats	[10, 144]
	FLJ34162	±	±	±	Up	Up		(type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain,	
	AB040878.1	±	±	±	±	±		(semaphorin) 5B	
HAMPS:	NM_018987.1	±	±	±	±	±	TD : 00	· 1 /	E1 45 7 1=3
SH3KBP1	FLJ54612	±	±	±	Dn	Dn	Differ	SH3-domain kinase binding protein 1	[145-147]
	FLJ54623	±	±	±	±	Up			
SPRED2	NM_031892.1 FLJ52731	± ±	±	± ±	± ±	± Up	Differ	sprouty-related, EVH1 domain containing 2	[10, 125, 126
	NM_181784.1	± ±	± ±	± ±	± ±	∪p ±	Dillel	sprouty-related, L v III domain containing 2	[10, 125, 126
TFEC	FLJ55256	±	Up	Up (1,783)	Up (676)	Up	Differ	transcription factor EC	[148]
	NM_012252.2	±	±	±	Up	Dn	Dinoi	F	[1-10]
ГМС5	FLJ54454	±	±	±	±	±	Differ	transmembrane channel-like 5	[149, 150]
	FLJ54906	±	±	Dn	Dn (104)	Dn (158)			[, 100]
	NM_024780.3	±	±	±	±	±			

Symbols used to indicate differences of mean averages of log2 ratios between the control (0-day) and experimental samples (1-day, 2-days, 7-days, 14-days and 35-days).

Numbers presented within parentheses are fold-changes.

 $^{: &}quot;\pm", \ 1/10 \ but < 10 - fold; "Dn", > 1/100 \ but \leq 1/10; "Up", \geq 10 - fold \ but < 100 - fold; "Dn()", \geq 1/100; \ and \ "Up()", \geq 100 - fold.$